LAWSUITS NEWS & LEGAL INFORMATION
Search Results for
Sort by date 2,440 pages found matching data breach- Yale University Pension Plan Lawsuit Heading to Jury Trial
Dec-12-22 Hartford, CT On October 21, 2022, the Federal District Court for the District of Connecticut held that participants in the Yale University Retirement Account Plan will have an opportunity to present their allegations of financial mismanagement to a jury. The ERISA lawsuit alleges that plan administrators violated their ERISA fiduciary duty t... - Prosthetic Denial Lawsuits Filed against UnitedHealth Group and Anthem under ERISA
Sep-24-18 Santa Clara, CA: Prosthetics with a variety of microprocessors are the new “wearable technology” and they’re making headlines. Companies have designed the devices with accelerometers, gyroscopes and magnetometers, state-of-the-art and cutting edge technology. But they aren’t available for every amputee who wants this advanced prosthetic limb techn... - Essure Side Effects Lawsuit News and Legal Information
Essure is a birth control device intended to cause permanent sterility without surgery, marketed and distributed by Bayer Healthcare. Since its approval in 2002, the FDA has received thousands of complaints about Essure side effects. Essure lawsuits have multiplied, and the FDA has required a ”black box” warning since 2016. Bayer has now take... - Alere INRatio Recall Legal News and Lawsuit Information
The Alere INRatio Monitoring System is a handheld device used by patients to monitor amounts of the blood-thinning drug Warfarin . While these drugs prevent blood clots , too little or too much can be life-threatening—accurate monitoring is crucial, especially if the patient is self-monitoring their blood levels at home. The INRatio2 system was... - Ozempic and Mounjaro Weight Loss Lawsuit News and Legal Information
Ozempic lawsuits allege Novo Nordisk failed to warn consumers that its diabetes and weight loss drug carries dangerous side effects, including severe gastroparesis (known as stomach paralysis), gastroenteritis, gallbladder disease and other serious health issues. Eli Lilly’s weight loss drug Mounjaro—and Ozempic’s competitor-- is also accus... - Never, Never Give Anyone Your Password, Ever!
Mar-30-15 New York, NY Right this very second a cyber criminal is out there trying to break into confidential information somewhere and figuring out ways to profit from that unauthorized access. Security expert Aaron Ross says consumers and corporations need to stay alert and be hypervigilant in order to keep from being towed under by the relentless, dangerous a... - Fosamax FAQ
What is Fosamax? Fosamax is the brand name for alendronate sodium. It is a bisphosphonate drug prescribed to treat osteoporosis in women after menopause, and to treat osteoporosis in men. It is also prescribed to advanced cancer and Paget's disease patients in order to help fight the thinning of bone common in those diseases. Fosamax is designed to... - Fosamax Side Effects - Fosamax and Femur Fractures, Fosamax Femur Lawsuit
Fosamax is prescribed to increase bone density in patients (mainly menopausal women) with osteoporosis. Fosamax side effects include Fosamax osteonecrosis , also known as Fosamax dead jaw, and recently Fosamax femur fractures . Osteonecrosis of the jaw (ONJ) is a disease in which bone tissue in the jaw does not heal after minor traumas such as tooth ex... - "Darvon and Darvocet trials will be bigger than Vioxx," predicts Dr. Ulf Jonasson
Jan-18-11 Stockholm, Sweden When Ulf Jonasson, Doctor of Public Health visited the US from Sweden in 2003 and again in 2004, he met with doctors at Public Citizen ; doctors who had received studies by Dr. Jonasson and his partner, Birgitta Jonasson, PhD, and were calling for a ban on Darvon (Dextropropoxyphene) , made by Eli Lilly. "We have researched Dar... - 401(k) Lawsuit Continues against Franklin Templeton
Oct-15-18 San Francisco, CA An ERISA pension plan lawsuit has survived numerous procedural challenges and will proceed as a class action against investment manager Franklin Templeton. Fernandez v. Franklin Resources Inc. claims that the fiduciaries in charge of managing the Franklin Templeton 401(k) Plan breached their duty to plan participants by causing... - When Employers Fail, ERISA Laws Protect Employee Benefit Plans
Jun-26-09 San Francisco, CA When it comes to providing employee stock options, there are rules that employers must follow to ensure the stock options are run to the benefit of employees who invest in stock option plans. The Employee Retirement Income Security Act (ERISA) mandates that fiduciaries, that is people who manage stock option and other benefit plans, fol... - Creeping Data Collection at Family Dollar, Dollar Tree
Jul-23-21 Chicago, IL Family Dollar collected Mantrise Herron’s fingerprints without her permission in apparent violation of Illinois’ Biometric Information Privacy Act (BIPA). BIPA is a privacy-protection law, and Herron v. Family Dollar Inc. is a class action privacy protection lawsuit. But privacy is increasingly a luxury for the well-heele... - Pharmaceuticals Fast-Tracked to Market through Little-Known FDA Protocol
Apr-20-17 New Orleans, LA: An interesting sidebar to Taxotere hair loss litigation has opened up through a peek into docetaxel hair loss multidistrict litigation, and an accompanying analysis of the various approval protocols employed to bring both branded and generic docetaxel (Taxotere) to the market. Most are familiar with the 510(k) Clearance protocol emp... - Jander ERISA Lawsuit Settles, but Leaves Questions
Jul-9-21 New York, NY Jander v. Retirement Plans Committee of IBM , a long-running employee stock ownership lawsuit , settled on April 2, 2021 for $4.75 million. The attorneys who represented the retirement plan participants have now requested $1.4 million in fees for the latest Supreme Court phase of the case. In deciding whether to approve the fee, the Southern... - Months-Long Investigation Uncovers Potential Consumer Data Misuse in Florida
Nov-15-16 Tampa, FL: While there are various federal laws in place designed to protect the privacy of the consumer, including misuse of phone numbers and contact information, an exhaustive investigation by electronic journalists in the state of Florida has uncovered a practice whereby private driver records are vended to various companies in exchange for payment to... - Trasylol Fiasco - FDA Fails To Protect Americans Again - Part II
Feb-4-08 Washington, DC: In reading the report issued by the Zuckerman Spaeder law firm, one thing is perfectly clear. Bayer was willing to pay $700,000 to get a Trasylol study done in time for the September 21, 2006 advisory committee meeting, if it could refute the findings of the New England Journal of Medicine study. However, unbeknownst to the contract re... - Trasylol Fiasco - FDA Fails To Protect Americans Again - Part I
Feb-1-08 Washington, DC: On November 5, 2007, the FDA announced that Bayer Pharmaceuticals had suspended the marketing of Trasylol after preliminary results of a Canadian study indicated that patients may also have a greater risk of death than patients taking either of two other drugs. The Canadian study, Blood Antifibrinolytics Randomized Trial (BART), led... - Vytorin Fraudulent Marketing Class Action Lawsuit
The makers of the cholesterol drug Vytorin are under fire for allegedly making false claims in their marketing campaign. New York Attorney-General Andrew Cuomo is investigating whether Vytorin's marketing campaign violated the state's laws regarding false advertising. Specifically, officials are concerned that, despite results from a study that found Vytorin... - Aranesp, Epogen, & Procrit Lawsuit News and Legal Information
Aranesp, Epogen, and Procrit -- three common drugs used to treat anemia -- have been linked to serious complications in cancer and kidney patients. The drugs, which are erythropoiesis stimulating agents (ESAs), have been approved to treat anemia in patients with chronic kidney failure and in cancer patients whose anemia is caused by chemotherapy. Epogen... - Business Booming for SSRI Makers
Jan-8-07 Washington, DC: The market for antidepressants is the largest segment of the Central Nervous System drug sector with global sales of $16.2 billion in 2005. Depression costs the US economy an estimated $44 billion a year and the World Health Organization predicts depression will be the leading cause of disability by 2020, according to a report by Research a...